Drugs.com - New Drug Approvals

FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the Treatment of Cystic Fibrosis

BOSTON--(BUSINESS WIRE)--Dec. 20, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class...

Feb 9, 2025 - 22:25
 0
FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the Treatment of Cystic Fibrosis
BOSTON--(BUSINESS WIRE)--Dec. 20, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class...
Read More

Tags:

Previous Article

Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Me...

Next Article

U.S. FDA Approves Pfizer’s Braftovi Combination Regimen as First-Line Treatment ...

Related Posts

FDA Approves Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) for Prevention of Invasive Meningococcal Disease Caused by Serogroups A, B, C, W, and Y

FDA Approves Penmenvy (meningococcal groups A, B, C, W,...

Feb 17, 2025  0

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Treatment of Diabetic Macular Edema

FDA Approves Genentech’s Susvimo as the First and Only ...

Feb 9, 2025  0

Rhythm Pharmaceuticals Announces FDA Approval of Imcivree (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces FDA Approval of Imcivr...

Feb 9, 2025  0